Table 2_Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review.xls

Table 2_Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review.xls

<p>Pralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation. However, adverse events associated with pralsetinib and se...

Full description

Saved in:
Bibliographic Details
Main Author: Kaidiriye Setiwalidi (14255810) (author)
Other Authors: Yimeng Li (4002950) (author), Yuyan Ma (169643) (author), Zhanpeng Hao (20287506) (author), Yujia Zhao (8929334) (author), Yuxin Zhang (168579) (author), Xuan Liang (3489464) (author), Tao Tian (602112) (author), Zhiping Ruan (3489467) (author), Yu Yao (428722) (author), Xiao Fu (74654) (author)
Published: 2024
Subjects:
Oncology and Carcinogenesis not elsewhere classified
NSCLC
RET
pralsetinib
selpercatinib
invasive aspergillosis
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items